{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:01:50Z","timestamp":1792530110291,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015756","name":"Cilag AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015756","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.clml.2025.03.004","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T11:31:03Z","timestamp":1741087863000},"page":"606-614.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Survival, Years of Life Lost and Attrition Rates in Multiple Myeloma Patients in France"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0131-8689","authenticated-orcid":false,"given":"Aurore","family":"Perrot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7611-371X","authenticated-orcid":false,"given":"Fanny","family":"Raguideau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8881-4679","authenticated-orcid":false,"given":"Helene","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4092-422X","authenticated-orcid":false,"given":"Martin","family":"Prodel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Javelot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Pierres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0275-2575","authenticated-orcid":false,"given":"Cyrille","family":"Touzeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.03.004_bib0001","series-title":"2019 IEEE Conference on Computational Intelligence in Bioinformatics and Computational Biology (CIBCB)","first-page":"1","article-title":"ATLAS: a robust algorithm for temporal sequence alignment of treatment lines using claim databases","author":"Prodel","year":"2019"},{"issue":"1","key":"10.1016\/j.clml.2025.03.004_bib0002","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/nyas.13038","article-title":"Multiple myeloma in the marrow: pathogenesis and treatments","volume":"1364","author":"Fairfield","year":"2016","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.clml.2025.03.004_bib0003","unstructured":"Myeloma - Cancer Stat Facts. SEER. Accessed March 5, 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"10.1016\/j.clml.2025.03.004_bib0004","unstructured":"Monnereau A., Remontet L., Maynadi\u00e9 M., et al. Estimation nationale de l'incidence des cancers en France entre 1980 et 2012 - partie 2- h\u00e9mopathies malignes. Partenariat Francim\/HCL\/InVS\/INCa. 2013. Accessed January 1, 2013. http:\/\/www.e-cancer.fr\/Expertises-et-publications\/Catalogue-des-publications\/Estimation-nationale-de-l-incidence-des-cancers-en-France-entre-1980-et-2012-Partie-2-Hemopathies-malignes."},{"key":"10.1016\/j.clml.2025.03.004_bib0005","unstructured":"Comprendre le my\u00e9lome multiple - Ref : GUIMYELMULT15. Accessed October 15, 2024. https:\/\/www.e-cancer.fr\/Expertises-et-publications\/Catalogue-des-publications\/Comprendre-le-myelome-multiple."},{"issue":"1","key":"10.1016\/j.clml.2025.03.004_bib0006","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12885-023-10787-5","article-title":"Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany","volume":"23","author":"Eisfeld","year":"2023","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.clml.2025.03.004_bib0007","doi-asserted-by":"crossref","first-page":"17272","DOI":"10.1038\/s41598-021-96804-8","article-title":"Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016","volume":"11","author":"Hemminki","year":"2021","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.clml.2025.03.004_bib0008","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/s41375-023-01852-w","article-title":"Survival in hematological malignancies in the Nordic countries through a half century with correlation to treatment","volume":"37","author":"Hemminki","year":"2023","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2025.03.004_bib0009","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41375-021-01453-5","article-title":"Mortality trends in multiple myeloma after the introduction of novel therapies in the United States","volume":"36","author":"Binder","year":"2022","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.clml.2025.03.004_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clml.2025.03.004_bib0011","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2025.03.004_bib0012","doi-asserted-by":"crossref","first-page":"962","DOI":"10.3390\/cancers15030962","article-title":"Attrition rates in multiple myeloma treatment under real world conditions-an analysis from the Austrian myeloma registry (AMR)","volume":"15","author":"Benda","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.clml.2025.03.004_bib0013","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41408-023-00883-x","article-title":"Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis","volume":"13","author":"McCurdy","year":"2023","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2025.03.004_bib0014","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1186\/s12885-020-07503-y","article-title":"Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma","volume":"20","author":"Fonseca","year":"2020","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.clml.2025.03.004_bib0015","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.therap.2018.09.076","article-title":"The value of a health insurance database to conduct pharmacoepidemiological studies in oncology","volume":"74","author":"Conte","year":"2019","journal-title":"Therapie"},{"issue":"12","key":"10.1016\/j.clml.2025.03.004_bib0016","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006189","article-title":"Identifying multiple myeloma patients using data from the French health insurance databases","volume":"96","author":"Palmaro","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"10.1016\/j.clml.2025.03.004_bib0017","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/pds.4233","article-title":"The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology","volume":"26","author":"Bezin","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clml.2025.03.004_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.therap.2023.01.009","article-title":"Performing pharmacoepidemiological studies using the French health insurance data warehouse (SNDS): how to translate guidelines into practice","author":"de Germay","year":"2023","journal-title":"Therapie"},{"issue":"7","key":"10.1016\/j.clml.2025.03.004_bib0019","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/j.1524-4733.2008.00350.x","article-title":"Estimation of life expectancy and the expected years of life lost in patients with major cancers: extrapolation of survival curves under high-censored rates","volume":"11","author":"Chu","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.clml.2025.03.004_bib0020","unstructured":"Population par sexe et groupe d\u2019\u00e2ges | Insee. Accessed June 27, 2024. https:\/\/www.insee.fr\/fr\/statistiques\/2381474."},{"issue":"9318","key":"10.1016\/j.clml.2025.03.004_bib0021","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/S0140-6736(02)08594-X","article-title":"Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls","volume":"359","author":"Pocock","year":"2002","journal-title":"The Lancet"},{"issue":"Suppl","key":"10.1016\/j.clml.2025.03.004_bib0022","article-title":"P938: survival of patients with multiple myeloma in the general population based on data from two French cancer registries","volume":"7","author":"Hulin","year":"2023","journal-title":"Hemasphere"},{"issue":"9","key":"10.1016\/j.clml.2025.03.004_bib0023","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(14)70282-7","article-title":"Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study","volume":"15","author":"Sant","year":"2014","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.clml.2025.03.004_bib0024","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.3324\/haematol.2023.282905","article-title":"Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study","volume":"108","author":"McCurdy","year":"2023","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.clml.2025.03.004_bib0025","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1200\/JCO.2009.25.2114","article-title":"Survival and years of life lost in different age cohorts of patients with multiple myeloma","volume":"28","author":"Ludwig","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2025.03.004_bib0026","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1200\/JCO.2009.25.2114","article-title":"Survival and years of life lost in different age cohorts of patients with multiple myeloma","volume":"28","author":"Ludwig","year":"2010","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.clml.2025.03.004_bib0027","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the Life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.03.004_bib0028","first-page":"e528","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"Hemasphere"},{"issue":"11","key":"10.1016\/j.clml.2025.03.004_bib0029","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.clml.2025.03.004_bib0030","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2025.03.004_bib0031","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","volume":"25","author":"P","year":"2024","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.clml.2025.03.004_bib0032","unstructured":"Multiple myeloma | Nature Reviews Disease Primers. Accessed October 15, 2024. https:\/\/www.nature.com\/articles\/s41572-024-00529-7."},{"issue":"7","key":"10.1016\/j.clml.2025.03.004_bib0033","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1002\/hem3.86","article-title":"Efficacy and safety of bendamustine-containing bridging therapy in R\/R LBCL patients receiving CD19 CAR T-cells","volume":"8","author":"Iacoboni","year":"2024","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2025.03.004_bib0034","unstructured":"ESMO. Clinical lymphoma myeloma and leukemia. Accessed October 15, 2024. https:\/\/www.esmo.org\/about-esmo\/discover-esmo-journals\/esmo-affiliated-journals\/clinical-lymphoma-myeloma-and-leukemia."},{"issue":"3","key":"10.1016\/j.clml.2025.03.004_bib0035","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/blood.2022017635","article-title":"How I treat multiple myeloma in geriatric patients","volume":"143","author":"Facon","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.03.004_bib0036","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","author":"Facon","year":"2024","journal-title":"N Engl J Med."}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T21:25:02Z","timestamp":1754429102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025000801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2152265025000801"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.03.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival, Years of Life Lost and Attrition Rates in Multiple Myeloma Patients in France","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}